Jul 17 |
FDA priority review advances Atara’s tabelecleucel for viral infection
|
Jul 17 |
Atara lead asset tab-cel undergoes FDA priority review
|
Jul 17 |
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
|
Jul 17 |
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
|
Jul 15 |
All You Need to Know About Atara Biotherapeutics (ATRA) Rating Upgrade to Strong Buy
|
Jul 3 |
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
|
Jul 3 |
Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy
|
Jun 21 |
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
|
Jun 17 |
Atara Biotherapeutics announces reverse split to regain Nasdaq compliance
|
Jun 17 |
Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
|